1. Home
  2. IFRX vs SPRU Comparison

IFRX vs SPRU Comparison

Compare IFRX & SPRU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • SPRU
  • Stock Information
  • Founded
  • IFRX 2007
  • SPRU 2008
  • Country
  • IFRX Germany
  • SPRU United States
  • Employees
  • IFRX N/A
  • SPRU N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • SPRU Auto Parts:O.E.M.
  • Sector
  • IFRX Health Care
  • SPRU Consumer Discretionary
  • Exchange
  • IFRX Nasdaq
  • SPRU Nasdaq
  • Market Cap
  • IFRX 53.5M
  • SPRU 48.7M
  • IPO Year
  • IFRX 2017
  • SPRU N/A
  • Fundamental
  • Price
  • IFRX $1.27
  • SPRU $2.84
  • Analyst Decision
  • IFRX Strong Buy
  • SPRU
  • Analyst Count
  • IFRX 5
  • SPRU 0
  • Target Price
  • IFRX $7.40
  • SPRU N/A
  • AVG Volume (30 Days)
  • IFRX 486.5K
  • SPRU 171.6K
  • Earning Date
  • IFRX 11-07-2025
  • SPRU 11-12-2025
  • Dividend Yield
  • IFRX N/A
  • SPRU N/A
  • EPS Growth
  • IFRX N/A
  • SPRU N/A
  • EPS
  • IFRX N/A
  • SPRU N/A
  • Revenue
  • IFRX $191,224.00
  • SPRU $98,396,000.00
  • Revenue This Year
  • IFRX N/A
  • SPRU $2.12
  • Revenue Next Year
  • IFRX $1,216.24
  • SPRU N/A
  • P/E Ratio
  • IFRX N/A
  • SPRU N/A
  • Revenue Growth
  • IFRX 54.36
  • SPRU 23.43
  • 52 Week Low
  • IFRX $0.71
  • SPRU $1.13
  • 52 Week High
  • IFRX $2.82
  • SPRU $3.41
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 47.77
  • SPRU 62.41
  • Support Level
  • IFRX $1.14
  • SPRU $2.65
  • Resistance Level
  • IFRX $1.44
  • SPRU $3.41
  • Average True Range (ATR)
  • IFRX 0.14
  • SPRU 0.28
  • MACD
  • IFRX -0.03
  • SPRU -0.03
  • Stochastic Oscillator
  • IFRX 26.00
  • SPRU 50.95

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About SPRU Spruce Power Holding Corporation

Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.

Share on Social Networks: